Meta-analysis of the Literature on Diagnostic Accuracy of SPECT in Parkinsonian Syndromes

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2007 Sep 4

PMID 17764571

Citations 45

Authors

Annemarie M M Vlaar

Marinus J P G van Kroonenburgh

Alfons G H Kessels

Wim E J Weber

Affiliations

Soon will be listed here.

Abstract

Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder. One of the most widely used techniques to diagnose PD is a Single Photon Emission Computer Tomography (SPECT) scan to visualise the integrity of the dopaminergic pathways in the brain. Despite this there remains some discussion on the value of SPECT in the differential diagnosis of PD. We did a meta-analysis of all the existing literature on the diagnostic accuracy of both pre- and post-synaptic SPECT imaging in the differential diagnosis of PD.

Methods: Relevant studies were searched in Medline, EMBASE and Cochrane databases with back-searching of their reference lists. We limited our analysis to studies with a clinically relevant methodology: i.e. when they assessed the ability of the SPECT to provide 1. diagnosis of PD in an early phase vs. normalcy; 2 diagnostic differentiation between PD and essential tremor (ET); 3. distinguishing between PD and vascular parkinsonism (VP); 4. delineation of PD from atypical parkinsonian syndromes (APS). Gold standard was, dependent on the study type, clinical examination at initial visit or follow-up, and/or response to dopaminergic agents.

Results: The search gave 185 hits, of which we deemed 32 suitable for our analysis. From these we recalculated the diagnostic odds ratio of SPECT for the clinical questions above. The pooled odds ratio (with 95%CI) for presynaptic SPECT scan's ability to distinguish between early PD and normalcy was 60 (13 - 277). For the ability to differentiate between PD and ET this ratio was 210 (79-562). The ratio for presynaptic SPECT's ability to delineate PD from VP was 105 (32 - 348). The mean odds ratio for the presynaptic SPECT scans to differentiate between PD and the two APS was 2 (1 - 4), and for the postsynaptic SPECT imaging this was 19 (9-36).

Conclusion: SPECT with presynaptic radiotracers is relatively accurate to differentiate patients with PD in an early phase from normalcy, patients with PD from those with ET, and PD from VP. The accuracy of SPECT with both presynaptic and postsynaptic tracers to differentiate between PD and APS is relatively low.

Citing Articles

Effect of Beta-Blocker Consumption on the Severity and Extension of Perfusion Defects in Dipyridamole Myocardial Perfusion Single-Photon Emission Computed Tomography.

Shahlaee S, Falsoleiman H, Daloee M, Gholoobi A, Divband G, Raeisi N World J Nucl Med. 2024; 23(3):191-198.

PMID: 39170841 PMC: 11335382. DOI: 10.1055/s-0044-1787887.

Advancing the Frontier: Neuroimaging Techniques in the Early Detection and Management of Neurodegenerative Diseases.

Akram A, Grezenko H, Singh P, Ahmed M, Hassan B, Hagenahalli Anand V Cureus. 2024; 16(5):e61335.

PMID: 38947709 PMC: 11213966. DOI: 10.7759/cureus.61335.

The role of SPECT/CT in painful, noninfected knees after knee arthroplasty: a systematic review and meta-analysis-a diagnostic test accuracy review.

Anzola L, Hernandez N, Rodriguez L, Sanguino G, Martinez E, Lopez R J Orthop Surg Res. 2023; 18(1):223.

PMID: 36945001 PMC: 10031962. DOI: 10.1186/s13018-023-03687-8.

Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia.

Kunz D, Stotz S, de Zeeuw J, Papakonstantinou A, Dumchen S, Haberecht M J Neurol Neurosurg Psychiatry. 2023; 94(7):532-540.

PMID: 36725328 PMC: 10314035. DOI: 10.1136/jnnp-2022-330048.

First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study.

Metta V, Ibrahim H, Loney T, Benamer H, Alhawai A, Almuhairi D J Pers Med. 2022; 12(8).

PMID: 36013249 PMC: 9410099. DOI: 10.3390/jpm12081300.

References

Koller W, Montgomery E . Issues in the early diagnosis of Parkinson's disease. Neurology. 1997; 49(1 Suppl 1):S10-25. DOI: 10.1212/wnl.49.1_suppl_1.s10. View

Bettin S, Kampfer I, Seese A, Schafer A, Reuter M, Lossner J . [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms]. Nuklearmedizin. 1997; 36(5):167-72. View

Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L . Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med. 1997; 38(11):1711-7. View

Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel W . [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord. 1997; 12(6):898-902. DOI: 10.1002/mds.870120610. View

Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Kunig G . 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord. 1998; 13(1):16-9. DOI: 10.1002/mds.870130107. View

Muller T, Farahati J, Kuhn W, Eising E, Przuntek H, Reiners C . [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol. 1998; 39(1):44-8. DOI: 10.1159/000007896. View

Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W . Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med. 1998; 39(6):954-60. View

Litvan I, MacIntyre A, Goetz C, Wenning G, Jellinger K, Verny M . Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998; 55(7):969-78. DOI: 10.1001/archneur.55.7.969. View

Messa C, Volonte M, Fazio F, Zito F, Carpinelli A, DAmico A . Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med. 1998; 25(9):1270-6. DOI: 10.1007/s002590050295. View

10.

Seibyl J, Marek K, Sheff K, Zoghbi S, Baldwin R, Charney D . Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998; 39(9):1500-8. View

11.

Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T . [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm (Vienna). 1999; 105(10-12):1213-28. DOI: 10.1007/s007020050124. View

12.

Booij J, Tissingh G, Winogrodzka A, van Royen E . Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999; 26(2):171-82. DOI: 10.1007/s002590050374. View

13.

Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel W . Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism. Neuroradiology. 1999; 41(2):124-8. DOI: 10.1007/s002340050716. View

14.

Lee M, Kim Y, Im J, Kim H, Rinne J, Bhatia K . 123I-IPT brain SPECT study in essential tremor and Parkinson's disease. Neurology. 1999; 52(7):1422-6. DOI: 10.1212/wnl.52.7.1422. View

15.

Assendelft W, van Tulder M, Scholten R, Bouter L . [The practice of systematic reviews. II. Searching and selection of studies]. Ned Tijdschr Geneeskd. 1999; 143(13):656-61. View

16.

Fahn S . Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol. 1999; 56(5):529-35. DOI: 10.1001/archneur.56.5.529. View

17.

Piccini P, Whone A . Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2004; 3(5):284-90. DOI: 10.1016/S1474-4422(04)00736-7. View

18.

Clarke C . Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. 2004; 3(8):466-74. DOI: 10.1016/S1474-4422(04)00823-3. View

19.

Pizzolato G, Cagnin A, Rossato A, Chierichetti F, Fabbri M, Dam M . Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Adv Neurol. 1996; 69:467-73. View

20.

Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J . Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996; 37(11):1760-5. View